micronavigation ELN path item Leukemias path item CML path item EUTOS Score  · 
Workpackage 4

Online calculation of the EUTOS Score

Created by: Schäfer , generated 2011/07/14 , last changed: 2011/11/15

The new EUTOS score predicts complete cytogenetic remission (CCgR) 18 months after the start of therapy, which is an important predictor for the course of disease. Patients without CCgR at this point of treatment are less likely to achieve one later on and are at a high risk of progressing to blastic and accelerated phase disease.

The strongest predictors for CCgR at 18 months are spleen size and percentage of basophils. Spleen size is measured in cm under the costal margin, basophils as their percent in peripheral blood. Both need to be assessed at baseline. Their relationship to CCgR is expressed by the formula:

7 * basophils + 4 * spleen size

If the sum is greater than 87, the patient is at high risk of not achieving a CCgR at 18 months, while a sum less than or equal to 87 indicates a low risk.

The following display calculates the result of the EUTOS score and the respective risk group. Additionally, the individual probability of the patient not to be in CCgR after 18 months is calculated.

Test
The EUTOS Score
CHRONIC MYELOID LEUKEMIA
ESTIMATION OF PROGNOSIS
Spleen:   max. distance from costal margin cm
Blood Basophils:   %
 
 
EUTOS Risk group: 
EUTOS Probability for no CCgr at 18 months: 
EUTOS Score: 
 
 
  • EUTOS Probability = Probability of the patient NOT to be in CCgR after 18 months of Imatinib therapy.
  • EUTOS Score: 7 * Basophils + 4 * Spleen size
    > 87 => high risk
    <= 87 => low risk
  • Hasford J et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-92. Epub 2011 May 2.
Notice
Spleen size and basophils must be measured and performed before any treatment. The score must not be used in pretreated patients.

 

Print this Document   Sitemap   Contact  
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top